SCHEMBL1124512

SCHEMBL1124512

O=C(O)C(Cc1ccccc1)N(Cc1ccc(-c2ccccn2)cc1)C(=O)C=Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.42
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.40
HTR5A P47898 3/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR7 P34969 1/20 0.39
ADRA1B P35368 1/20 0.39
DRD3 P35462 1/20 0.39
HTR2B P41595 1/20 0.39
HDAC1 Q13547 1/20 0.38
PPARG P37231 2/20 0.38
MDM2 Q00987 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1124509 1.00 TRPV1 (0.42) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL1124510 1.00 TRPV1 (0.42) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL1124430 0.91 NOS3 (0.51) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL1124428 0.91 NOS3 (0.51) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL1124433 0.91 NOS3 (0.51) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL2374005 0.89 ESR1 (0.37) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL2374011 0.89 ESR1 (0.37) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL2375324 0.89 TRPV1 (0.40) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL2375311 0.89 TRPV1 (0.40) TRPV1NOS3NOS1NOS2TRPM8
SCHEMBL2375316 0.89 TRPV1 (0.40) TRPV1NOS3NOS1NOS2TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281869-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS AISSAOUI HAMED (FR) 2011-11-17 US disclosed
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed
EP-2282996-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS Actelion Pharmaceuticals Ltd. (CH) 2011-02-16 EP disclosed
WO-2009141782-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 TRPV1 2628/4885NOS3 783/4885NOS1 996/4885
US-20110281869-A1 TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS QTRT2, RECQL, QTRT1 TRPV1 2524/4885NOS3 1013/4885NOS1 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.